MediciNova, Inc. — Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. The primary programs are MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases; the pipeline also includes MN-221 and MN-029.
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2018. The company has incurred significant losses since inception and does not have commercial product revenue.
Financial Position and Results
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No revenue recognized | No revenue recognized |
| Research, development and patents | $2.4 million | $5.4 million |
| General and administrative | $4.7 million | $9.7 million |
| Total operating expenses | $7.0 million | $15.1 million |
| Net loss | $6.8 million | $14.5 million |
| Net loss per share | $0.16 | $0.35 |
| Operating cash flow | Not separately provided | $(7.5) million |
Gross and operating margins are not meaningful because the company reported no revenue. Interest income was $0.3 million for the quarter and $0.7 million for the nine-month period. Stock-based compensation was $4.7 million for the quarter and $8.1 million for the nine months, substantially offsetting reported losses on a cash basis.
At September 30, 2018, cash and cash equivalents were $62.4 million, compared with $28.0 million at December 31, 2017. Working capital was approximately $61.0 million. Total liabilities were $3.7 million, including $1.7 million of deferred revenue; the filing does not report debt outstanding. Goodwill was $9.6 million and in-process research and development was $4.8 million.
Material Changes Versus the Prior Comparable Period
- Quarterly net loss increased to $6.8 million from $3.8 million, while nine-month net loss increased to $14.5 million from $9.6 million.
- Quarterly research and development expense increased to $2.4 million from $1.3 million, primarily from higher MN-166 clinical study costs and performance-based stock compensation.
- Quarterly general and administrative expense increased to $4.7 million from $2.5 million, mainly due to higher performance-based stock compensation.
- Nine-month operating cash usage increased to $7.5 million from $5.9 million.
- Financing cash inflows increased to $41.3 million from $6.3 million, primarily due to a February 2018 public offering and warrant exercises.
- The company issued 4,545,928 shares in the public offering and received approximately $38.5 million of net proceeds; shares outstanding increased to 41.9 million from 36.5 million at year-end 2017.
- The joint venture investment was liquidated, generating approximately $0.6 million of investing cash proceeds.
Guidance, Outlook, Risks and Unusual Items
Management expects substantial net losses to continue for the next several years as development programs advance. The company expects research and development spending to increase during 2018 and intends to pursue strategic partnerships to support later-stage development and commercialization.
Management stated that available cash and working capital were sufficient to fund operations at least through December 31, 2019, but cautioned that resources may not support all planned research and development programs. The company may need additional capital and has an ATM facility with up to $30.0 million of aggregate offering capacity; no shares were sold under that facility during the first nine months of 2018.
The Kissei collaboration contains approximately $1.7 million of long-term deferred revenue. No related revenue was recognized during the periods presented, and the second required study had not begun as of September 30, 2018.
Key risks include clinical-trial failure or delay, inability to obtain regulatory approval, dependence on MN-166 and MN-001, reliance on third parties, inability to secure partners or financing, market acceptance and reimbursement uncertainty, intellectual-property disputes, manufacturing constraints, and dilution from future equity issuance. No material legal proceedings or material changes to previously disclosed risk factors were reported.
Disclosure controls and procedures were assessed as effective at the reasonable-assurance level, with no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Progress, enrollment, results and funding sources for MN-166 clinical programs, particularly progressive multiple sclerosis and ALS.
- Development milestones and financing requirements for MN-001 and the remaining pipeline programs.
- Cash-burn trends and whether the stated cash runway remains sufficient as clinical spending increases.
- Potential dilution from outstanding options, including 6.6 million options outstanding at September 30, 2018, and future equity offerings.
- The timing and economics of the unstarted Kissei study and recognition of deferred revenue.
- Whether strategic partnerships or non-dilutive funding are secured to support later-stage development and commercialization.